ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Manzanilla Sophia®

Its studies are mostly in Asthenopia, led by Laboratorios Sophia S.A de C.V.

Furthest: phase 4, since Apr 15, 20242 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laboratorios Sophia S.A de C.V.20 open or runningphase 4since Apr 15, 2024Apr 15, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 15, 2024First study: phase 4 study in AsthenopiaFirst studyNCT06373653
  2. Feb 27, 2025Phase 4 study in Ophthalmological Agent ToxicityNCT06859476 · 167 enrolled · Mexico

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06859476Ophthalmological Agent Toxicity · Mexico4CompletedSep 23, 2025167
NCT06373653Asthenopia4WithdrawnFeb 11, 20250

How it is read

Names in the registry

  • “Manzanilla Sophia®”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.